Altering Chemosensitivity by Modulating Translation Elongation
Open accessThe DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The process of translation occurs at a nexus point downstream of a number of signal pathways and developmental processes. Modeling activation of the PTEN/AKT/mTOR pathway in the Emu-Myc mouse is a valuable tool to study tumor genotype/chemosensitivity relationships in vivo. In this model, blocking translation initiation with silvestrol, an inhibitor of the ribosome recruitment step has been showed to modulate the sensitivity of the tumors to the effect of standard chemotherapy. However, inhibitors of translation elongation have been tested as potential anti-cancer therapeutic agents in vitro, but have not been extensively tested in genetically well-defined mouse tumor models or for potential synergy with standard of care agents. METHODOLOGY/PRINCIPAL FINDINGS: Here, we chose four structurally different chemical inhibitors of translation elongation: homoharringtonine, bruceantin, didemnin B and cycloheximide, and tested their ability to alter the chemoresistance of Emu-myc lymphomas harbouring lesions in Pten, Tsc2, Bcl-2, or eIF4E. We show that in some genetic settings, translation elongation inhibitors are able to synergize with doxorubicin by reinstating an apoptotic program in tumor cells. We attribute this effect to a reduction in levels of pro-oncogenic or pro-survival proteins having short half-lives, like Mcl-1, cyclin D1 or c-Myc. Using lymphomas cells grown ex vivo we reproduced the synergy observed in mice between chemotherapy and elongation inhibition and show that this is reversed by blocking protein degradation with a proteasome inhibitor. CONCLUSION/SIGNIFICANCE: Our results indicate that depleting short-lived pro-survival factors by inhibiting their synthesis could achieve a therapeutic response in tumors harboring PTEN/AKT/mTOR pathway mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This effect likely occurs because harringtonine binds to free 60s subunits, but not those that are joined into an 80s ribosome. Thus, elongating ribosomes are immune to harringtonine, whereas a 60s subunit bound by harringtonine will form an 80s at a start site that does not move forward”
From Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes (2011) · cites this paper as Robert et al., 2009
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Median effect analysis indicated a combination index (CI) below 1 for Dxr+HHT and Rap+Dxr indicative of synergy [40] (Fig 7B).”
BackgroundUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 1×
“40S ribosome (and associated factors) [7].”
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169 · cited 3×
“oncogenes may be too narrow an approach for drug development, but rather targeting nodes that reside downstream of these pathways may offer broader acting therapies [1,2].”
BackgroundThe Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833 · cited 3×
“oncogenes may be too narrow an approach for drug development, but rather targeting nodes that reside downstream of these pathways may offer broader acting therapies [1,2].”
BackgroundRock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524 · cited 1×
“some-inhibitor MG132 [38].”
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 1×
“Several of the proteins that play important regulatory roles in cancer progression and apoptosis have short half-lives (e.g. cyclin D1 (∼25 min)”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446 · cited 1×
“S1), as well as identified as genotype-selective antitumor agents in synthetic lethal screens [41].”
BackgroundTranslational control of gene expression
Sonenberg, N., Hershey, J. W. B., & Mathews, M. B. (2000) · Cold Spring Harbor Laboratory eBooks · Cited by 1,379
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188 · cited 1×
“and c-Myc controls the expression of genes involved in many aspects of cell growth including cell cycle progression and survival”
BackgroundMalignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Self-citationeIF-4E expression and its role in malignancies and metastases
De Benedetti, A., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728 · cited 1×
“[10,11,12].”
Pelletier, J., & Sonenberg, N. (1985) · Cell · doi:10.1016/0092-8674(85)90200-4 · Cited by 610 · cited 1×
“. Increased eIF4F activity stimulates preferentially the translation of mRNA with G+C rich, highly-structured 5′UTRs (weak mRNAs) without significantly affecting translation of mRNAs with short and unstructured 5′UTRs (strong mRNAs)”
BackgroundSelf-citationElimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., & Wang, X. (2003) · Genes & Development · doi:10.1101/gad.1093903 · Cited by 591 · cited 2×
“For example, the anti-apoptotic factor Mcl-1, a short-lived Bcl-2 family member essential for normal haematopoiesis and constitutively targeted to the proteasome by the E3 Ligase MULE [29], is rapidly degraded upon UV-irradiation [30] or HHT treatment [31]. c-Myc protein levels have been shown to rapidly decline upon…”
BackgroundThe translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 586 · cited 1×
“eIF4E is oncogenic in vivo and in Em-Myc lymphomas over-expressing this factor, rapamycin is unable to modulate chemosensitivity whereas silvestrol can [6,16,18,19].”
BackgroundARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor
Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., & Gu, W. (2005) · Cell · doi:10.1016/j.cell.2005.03.037 · Cited by 544 · cited 1×
“. The level of these proteins is particularly sensitive to ongoing protein synthesis rates and can be affected by cellular stresses or treatment with translation inhibitors in cell culture. For example, the anti-apoptotic factor Mcl-1, a short-lived Bcl-2 family member essential for normal haematopoiesis and constitut…”
BackgroundProteins encoded by the human c-myc oncogene: differential expression in neoplastic cells.
Hann, S. R., & Eisenman, R. N. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.11.2486 · Cited by 495 · cited 1×
“cyclin D1 (,25 min) [26]; c-Myc (,25 min) [27]; myeloid cell leukemia1 (Mcl-1) (,40 min) [28].”
Duncan, R., Milburn, S. C., & Hershey, J. W. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)75938-9 · Cited by 482 · cited 1×
“for translation [8,9].”
Rajasekhar, V. K., Viale, A., Socci, N. D., Wiedmann, M., Hu, X., & Holland, E. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00395-2 · Cited by 420 · cited 1×
“(Mcl-1) and survivin [13,14,15].”
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
Wuillème-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., Harousseau, J.-L., Amiot, M., & Bataille, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403784 · Cited by 335 · cited 1×
“The role of Mcl-1 in enhancing cell survival by blocking activation of the pro-apoptotic factors Bak and Bax has been well-established in culture [39,59,60] and c-Myc controls the expression of genes involved in many aspects of cell growth including cell cycle progression and survival [61].”
BackgroundTargeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy
Graff, J. R., Konicek, B. W., Carter, J. H., & Marcusson, E. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5635 · Cited by 332 · cited 1×
“(Mcl-1) and survivin [13,14,15].”
Bordeleau, M.-E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H.-G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34753 · Cited by 332 · cited 6×
“Similar results have been documented for the mTOR inhibitor, rapamycin [5,6], and the eIF4A modulator, silvestrol [17], and suggests that the tumors derived from the Em-Myc model require a DNA damage trigger to undergo apoptosis when translation is inhibited.”
BackgroundMethodResultInfluentialSelf-citationDevelopmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes.
Merino, R., Ding, L., Veis, D. J., Korsmeyer, S. J., & Nuñez, G. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06307.x · Cited by 301 · cited 1×
“This could be due to the longer half-life of this anti-apoptotic factor (,10 hrs) [64] combined to the only partial inhibition of protein synthesis achieved in vivo by these compounds (Fig.”
BackgroundInhibition of translation in eukaryotic systems by harringtonine
FRESNO, M., JIMÉNEZ, A., & VÁZQUEZ, D. (1977) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1977.tb11256.x · Cited by 295 · cited 2×
“[33,37], suggesting that the compounds allow ribosome run-off.”
BackgroundmTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285 · cited 2×
“For this purpose, we used Tsc2 Em-Myc lymphomas cultured ex vivo [20].”
BackgroundMethodSelf-citationGSK-3β regulates cyclin D1 expression: A new target for chemotherapy
Takahashi-Yanaga, F., & Sasaguri, T. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.10.018 · Cited by 261 · cited 1×
“Cyclin D1 has been shown to bind to CDK4 and CDK6 leading to inactivation of Rb1, thus facilitating the transition from G1 to S phase and overcoming the transition inhibition by cyclin dependent kinase inhibitors [62,63].”
BackgroundEpigenetic Activation of a Subset of mRNAs by eIF4E Explains Its Effects on Cell Proliferation
Mamane, Y., Petroulakis, E., Martineau, Y., Sato, T.-A., Larsson, O., Rajasekhar, V. K., & Sonenberg, N. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000242 · Cited by 224 · cited 1×
“The mechanism by which Rap and silvestrol alter chemosensitivity is not clear but may involve remodelling of the oncoproteome through differential mRNA recruitment into initiation complexes [13], with preferred inhibition of ‘‘weak’’ mRNAs encoding pro-survival signals, such as Mcl-1 [4,17,20]”
BackgroundRapid Turnover of Mcl-1 Couples Translation to Cell Survival and Apoptosis
Adams, K. W., & Cooper, G. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610643200 · Cited by 170 · cited 2×
“These results are in agreement with previous work that showed that MG132 can protect against CHXinduced apoptosis in U397 cells [39].”
BackgroundResultTang, R., Faussat, A.-M., Majdak, P., Marzac, C., Dubrulle, S., Marjanovic, Z., Legrand, O., & Marie, J.-P. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0164 · Cited by 151 · cited 1×
“For example, the anti-apoptotic factor Mcl-1, a short-lived Bcl-2 family member essential for normal haematopoiesis and constitutively targeted to the proteasome by the E3 Ligase MULE [29], is rapidly degraded upon UV-irradiation [30] or HHT treatment [31].”
BackgroundHarringtonine, an Inhibitor of Initiation of Protein Biosynthesis
HUANG, M.-T. (1975) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10662-7 · Cited by 144 · cited 1×
“[33,37], suggesting that the compounds allow ribosome run-off.”
BackgroundInhibitors of protein synthesis identified by a high throughput multiplexed translation screen
Novac, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh235 · Cited by 140 · cited 1×
“Ribosome binding experiments were performed as previously described [24].”
MethodA pivotal role for Mcl-1 in Bortezomib-induced apoptosis
Podar, K., Gouill, S. L., Zhang, J., Opferman, J. T., Zorn, E., Tai, Y., Hideshima, T., Amiot, M., Chauhan, D., Harousseau, J., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210679 · Cited by 129 · cited 1×
“The role of Mcl-1 in enhancing cell survival by blocking activation of the pro-apoptotic factors Bak and Bax has been well-established in culture [39,59,60] and c-Myc controls the expression of genes involved in many aspects of cell growth including cell cycle progression and survival [61].”
BackgroundAntitumor Activity of Bruceantin: An Old Drug with New Promise,
Cuendet, M., & Pezzuto, J. M. (2003) · Journal of Natural Products · doi:10.1021/np030304+ · Cited by 125 · cited 1×
“Bruceantin [(Bru); a quassinoid], showed efficacy in a RPMI 8226 human-SCID xenografts mouse model [23].”
BackgroundQuintás‐Cardama, A., Kantarjian, H. M., Garcia‐Manero, G., O'Brien, S. M., Faderl, S. H., Estrov, Z. E., Giles, F. J., Murgo, A. J., Laddie, N., Verstovšek, S., et al. (2006) · Cancer · doi:10.1002/cncr.22398 · Cited by 125
Mode of Action of the Antitumor Compound Bruceantin, an Inhibitor of Protein Synthesis
Liao, L. L., Kupchan, S. M., & Horwitz, S. B. (1976) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11141-3 · Cited by 121 · cited 1×
“Both compounds inhibit the peptidyl transferase reaction [33,34,35,36] and are”
BackgroundDeterminants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo
Wendel, H.-G., Malina, A., Zhao, Z., Zender, L., Kogan, S. C., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0419 · Cited by 97 · cited 6×
“Similar results have been documented for the mTOR inhibitor, rapamycin [5,6], and the eIF4A modulator, silvestrol [17], and suggests that the tumors derived from the Em-Myc model require a DNA damage trigger to undergo apoptosis when translation is inhibited.”
BackgroundResultInfluentialSelf-citationApoptosis and chemoresistance in transgenic cancer models
Schmitt, C. A., & Lowe, S. W. (2001) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0293-3 · Cited by 78 · cited 1×
“One approach to study genotype-drug response relationships has been the use of mechanism-based mouse cancer models, such as the Em-Myc lymphoma model [3].”
MethodSelf-citationSchubert, K. M., & Duronio, V. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3560473 · Cited by 78 · cited 1×
“cyclin D1 (,25 min) [26]; c-Myc (,25 min) [27]; myeloid cell leukemia1 (Mcl-1) (,40 min) [28].”
Sah, N. K., Munshi, A., Kurland, J. F., McDonnell, T. J., Su, B., & Meyn, R. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211010200 · Cited by 70 · cited 1×
“Finally, translation elongation inhibitors have been shown to sensitize PC3 cells to TRAIL-induced apoptosis [48] and A549 lung cancer or K562 leukemia cells to cisplatin [49].”
BackgroundLarsson, O., Perlman, D. M., Fan, D., Reilly, C. S., Peterson, M., Dahlgren, C., Liang, Z., Li, S., Polunovsky, V. A., Wahlestedt, C., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl558 · Cited by 64
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
Tourneau, C., Raymond, E., & Faivre, S. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782360555 · Cited by 56 · cited 1×
“Aplidine [a didemnim (Did) family member] has shown activity in phase I clinical trials for many cancer types but especially in advanced medullar thyroid carcinoma [22].”
BackgroundBai, J., & Cederbaum, A. I. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110007 · Cited by 56 · cited 1×
“Differences in underlying genetic lesions among tumors could be responsible for these different responses [53].”
BackgroundCyclin degradation for cancer therapy and chemoprevention
Freemantle, S. J., Liu, X., Feng, Q., Galimberti, F., Blumen, S. R., Sekula, D., Kitareewan, S., Dragnev, K. H., & Dmitrovsky, E. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21519 · Cited by 46 · cited 1×
“Cyclin D1 has been shown to bind to CDK4 and CDK6 leading to inactivation of Rb1, thus facilitating the transition from G1 to S phase and overcoming the transition inhibition by cyclin dependent kinase inhibitors [62,63].”
BackgroundMechanism of eukaryotic protein synthesis inhibition by brusatol
Willingham, W., Stafford, E. A., Reynolds, S. H., Chaney, S. G., Lee, K.-H., Okano, M., & Hall, I. H. (1981) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(81)90168-4 · Cited by 36 · cited 1×
“Both compounds inhibit the peptidyl transferase reaction [33,34,35,36] and are”
BackgroundAbrogation of adriamycin toxicity in vivo by cycloheximide
Thakker, N., & Potten, C. S. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90697-h · Cited by 36 · cited 1×
“In other settings however, CHX and anguidine have protected cells against the cytotoxic effects of antitumor drugs [50,51,52].”
BackgroundAlarcon-Vargas, D., Tansey, W. P., & Ronai, Z. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205543 · Cited by 36
Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer
Benvenuto, J. A., Newman, R. A., Bignami, G. S., Raybould, T. J. G., Raber, M. N., Esparza, L., & Walters, R. S. (1992) · Investigational New Drugs · doi:10.1007/bf00873128 · Cited by 35 · cited 1×
“8 hrs [56] and its observed terminal half-life in mice is”
BackgroundClinical pharmacology of homoharringtonine.
Savaraj, N., Lu, K., Dimery, I. W., Feun, L. G., Burgess, M., Keating, M. J., & Loo, T. L. (1986) · PubMed · Cited by 29
Heys, S. D., Park, K. G. M., McNurlan, M. A., Calder, A. G., Buchan, V., Blessing, K., Eremin, O., & Garlick, P. J. (1991) · Clinical Science · doi:10.1042/cs0800587 · Cited by 26 · cited 1×
“Why would inhibiting translation elongation achieve a therapeutic index, since it is expected that translation of all mRNAs would be inhibited to the same extent by such inhibitors? It is possible that, by having higher translation rates [4,65] transformed cells are more sensitive to these compounds even when they exe…”
BackgroundUsing small molecules to overcome drug resistance induced by a viral oncogene
Smukste, I., Bhalala, O. G., Persico, M., & Stockwell, B. R. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.012 · Cited by 25 · cited 1×
“CHX has been reported to enhance the cytotoxicity of the anthracycline, epirubicin, against P388 murine leukemic cells [42] and to potentiate Dxr toxicity in RKO-E6 cells [43].”
BackgroundBudihardjo, I. I., Boerner, S. A., Eckdahl, S., Svingen, P. A., Rios, R., Ames, M. M., & Kaufmann, S. H. (2000) · Molecular Pharmacology · doi:10.1124/mol.57.3.529 · Cited by 25 · cited 2×
“Finally, translation elongation inhibitors have been shown to sensitize PC3 cells to TRAIL-induced apoptosis [48] and A549 lung cancer or K562 leukemia cells to cisplatin [49].”
BackgroundKano, Y., Sakamoto, S., Kasahara, T., Akutsu, M., Inoue, Y., & Miura, Y. (1991) · Leukemia Research · doi:10.1016/0145-2126(91)90112-7 · Cited by 23 · cited 1×
“Sparsomycin, pretazettine, and HHT also show synergy with antitumor agents against tumor cells ex vivo [44,45,46,47].”
BackgroundSelective inhibition of the polypeptide chain elongation in eukaryotic cells
Tujebajeva, R. M., Graifer, D. M., Matasova, N. B., Fedorova, O. S., Odintsov, V. B., Ajtkhozhina, N. A., & Karpova, G. G. (1992) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(92)90484-h · Cited by 21 · cited 1×
“Both compounds inhibit the peptidyl transferase reaction [33,34,35,36] and are”
BackgroundSakai, T., Aoike, A., Marui, N., Kawai, K., Nishino, H., & Fukushima, M. (1989) · PubMed · Cited by 21
30 Therapeutic Opportunities in TranslationPreprint
Pelletier, J., & Peltz, S. (2007) · Cold Spring Harbor Monograph Archive · doi:10.1101/087969767.48.855 · Cited by 17
Self-citationFurusawa, E., Lum, M. K. M., & Furusawa, S. (2009) · Chemotherapy · doi:10.1159/000237992 · Cited by 16 · cited 1×
“Sparsomycin, pretazettine, and HHT also show synergy with antitumor agents against tumor cells ex vivo [44,45,46,47].”
BackgroundPharmacokinetics of homoharringtonine in dogs
Lu, K., Savaraj, N., Feun, L. G., Guo, Z., Umsawasdi, T., & Loo, T. L. (1988) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257360 · Cited by 16 · cited 1×
“6 hrs in dogs [55].”
Hromas, R., Barlogie, B., Swartzendruber, D. E., & Drewinko, B. (1983) · PubMed · Cited by 11
Beasley, V. R., Bruno, S. J., Burner, J. S., Choi, B. W., RINEHART, K. L. J., KORITZ, G. D., & Levengood, J. M. (2005) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.466 · Cited by 10 · cited 1×
“and its observed terminal half-life in mice is 16.2 hrs”
BackgroundInfluentialClinical pharmacology of bruceantin by radioimmunoassay
Fong, K.-L. L., Ho, D. H., Benjamin, R. S., Brown, N. S., Bedikian, A. Y., Yap, B. S., Wiseman, C. L., Kramer, W. G., & Bodey, G. P. (1982) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257747 · Cited by 10 · cited 1×
“8 hrs depending on the patients [58].”
In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesis.
Żylicz, Z., Wagener, D. J. T., van Rennes, H., et al. (1987) · PubMed · Cited by 9
In Vitro Modulation of Cisplatin Cytotoxicity by Sparsomycin Inhibition of Protein Synthesis 2
Żylicz, Z., Wagener, D. J. T., van Rennes, H., Wessels, J. M. C., van der Kleijn, E., DeGrip, W. J., van den Broek, L. A. G. M., & Ottenheijm, H. C. J. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/78.4.701 · Cited by 9 · cited 1×
“Sparsomycin, pretazettine, and HHT also show synergy with antitumor agents against tumor cells ex vivo [44,45,46,47].”
BackgroundHofs, H. P., Wagener, D. J. T., Valk-Bakker, V. D., van Rennes, H., Ottenheijm, H. C. J., & Grip, W. J. D. (1994) · Anti-Cancer Drugs · doi:10.1097/00001813-199402000-00006 · Cited by 4
Augmentation of epirubicin cytotoxicity by cycloheximide.
FURUSAWA, S., Nakano, S., Wada, M., Chiba, H., Takayanagi, M., Takayanagi, Y., & SASAKI, K.-I. (1996) · PubMed · Cited by 3
Research works printed but not linked: 2
- H-G Wendel, 2004, Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy., Nature, 428, 332, 10.1038/nature02369 · DOI · Paper page
- JR Mills, 2008, mTORC1 promotes survival through translational control of Mcl-1., Proc Natl Acad Sci U S A, 105, 10853, 10.1073/pnas.0804821105 · DOI · Paper page
Cited by
Ingolia, N. T., Lareau, L. F., & Weissman, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.10.002 · Cited by 2,187
“We first stopped new translation using harringtonine, which effectively blocks initiation by inhibiting elongation during the first rounds of peptide bond formation following subunit joining (Fresno et al., 1977; Robert et al., 2009).”
MethodInfluentialIngolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., & Weissman, J. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.086 · Cited by 1,259
Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin
Schneider-Poetsch, T., Ju, J., Eyler, D. E., Dang, Y., Bhat, S., Merrick, W. C., Green, R., Shen, B., & Liu, J. O. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.304 · Cited by 1,014
“304-annotation-312">CHX seemed to slightly stabilize the RNA species, as has been observed befor”
ResultAMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B. J., Viollet, B., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.001 · Cited by 911
“Wewould like to thank Connie Krawczyk, Arnim Pause, Jerry Pelletier, Francis Robert, David Shackelford, and Leah Donnelly for technical and administrative help.”
MethodDecoding Human Cytomegalovirus
Stern-Ginossar, N., Weisburd, B., Michalski, A., Le, V. T. K., Hein, M. Y., Huang, S.-X., Ma, M., Shen, B., Qian, S.-B., Hengel, H., et al. (2012) · Science · doi:10.1126/science.1227919 · Cited by 589
Metadata
- Authors
- Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J.
- Affiliations
- McGill University (CA)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Pelletier, Jerry
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-05-01
- Volume
- 4
- Issue
- 5
- Pages
- e5428
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2671598
- OpenAlex
- W2012346470
- Cited by
- 90
- References
- 67
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 8 · 2013: 13 · 2012: 12
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Canadian Institutes of Health Research (79385_1)
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- chemosensitivity, chemoresistance, Eμ-Myc lymphoma, homoharringtonine, bruceantin, didemnin B, cycloheximide, doxorubicin synergy, apoptosis, Mcl-1, cyclin D1, c-Myc, eIF4E, TSC2, proteasome inhibition, ribosome recruitment
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Homoharringtonine, Animals, Base Sequence, Cycloheximide, Female, Harringtonines, Lymphoma, Mice, Inbred C57BL, Mutation, Peptide Chain Elongation, Translational, Genes, myc, Proto-Oncogene Proteins c-myc, DNA Primers, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Genes, bcl-2, Cyclin D1, Tumor Suppressor Proteins, Quassins, Eukaryotic Initiation Factor-4E, Cell Line, Tumor, Depsipeptides, PTEN Phosphohydrolase, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.